3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
9
Fallopian Tube Neoplasms
8
Neoplasms
6
Prostatic Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Recurrence
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
rucaparib
×
Clear all
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts